IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Novartis ac quired Bris tol-Myers Squibb’s US and Ca na dian OTC and con sumer prod ucts busi ness for
$660 mil lion in cash.
Novartis ac quired the pri vate Ger man ge neric phar ma ceu ti cal com pany Hexal from its own ers, Thomas
and Andreas Struengmann. Novartis also took a 67.7% stake (65.4% fully di luted) in the fast-grow ing
US generics com pany Eon Labs, in which the broth ers had an in di rect ma jor ity hold ing. The to tal cost of
this ac qui si tion was Euro5.65 million.
• Year: 2004
Sandoz ac quired AstraZeneca’s generics unit Durascan in Den mark for an un dis closed sum. This gave
Sandoz an op er a tion base for the Nordic mar ket and a solid po si tion in the Dan ish generics market.
Sandoz ac quired Sabex Hold ings, Can ada’s larg est in ject able generics com pany, in a $565 mil lion cash
trans ac tion (six times the com pany’s rev e nue), of fer ing Sandoz ac cess to Sabex’s ster ile man u fac tur ing
spe cialty ex per tise (com plete with dif fi cult to gain FDA man u fac tur ing sta tus), as well as en try into the
Canadian generics sector.
Hexal ac quired the pro duc tion fa cil ity of esparma (Ger many) in Osterweddingen as its sales and mar ket -
ing busi ness was bought by Wockhardt (In dia).
Hexal ac quired an FDA-cer ti fied chem i cals syn the sis fa cil ity in Radebeul/Dresden from Degussa (Ger -
many) for an un dis closed price.
• Year: 2003
Novartis’ Med i cal Nu tri tion Prod ucts di vi sion ac quired the Adult Nu tri tional busi ness of Mead John son &
Com pany (a sub sid iary of Bris tol-Myers Squibb) for $385 million.
Novartis paid $255m for 50% own er ship of pri vately owned Idenix (USA), gain ing ac cess to its late stage
an ti vi ral in R&D for hep a ti tis B (telbivudine) and an oral ther apy for hep a ti tis C.
It was re ported that Novartis had boosted its stake in Roche to 32.7%. But the fam ily shareholding pool
that con trols Roche has sig naled that it is still not in ter ested in a merger.
• Year: 2002
Novartis ac quired ge neric man u fac turer, Lek (Slovenia) for Euro860 mil lion.
• Year: 2001
Ac quired a 20% vot ing stake in Roche (Swit zer land) from Swiss in ves tor Mar tin Ebner’s BZ Group, fuel -
ling spec u la tion of a merger.
Novartis Generics ac quired Lagap Pharmaceuticals (UK) from Adcock Ingram (South Af rica).
Novartis and BioTransplant’s (USA) joint ven ture Im merge BioTherapeutics for the de vel op ment of
xenotransplantation was in au gu rated. Novartis owns 67% and BioTransplant 33%.
Hexal’s sub sid iary in Ar gen tina, Boxalpharma, merged with Lanpharm to form Hexal Ar gen tina.
Hexal’s unit in Tur key, Ilsan Iltas, ac quired Koz Pharmaceuticals/Biokem.
© 2009 IMS Health In cor po rated or its af fil i ates Page 139